AVE 0118

Drug Profile

AVE 0118

Alternative Names: AVE0118

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Antiarrhythmics
  • Mechanism of Action Potassium channel antagonists; Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Sleep apnoea syndrome
  • Discontinued Atrial fibrillation; Ventricular fibrillation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Sleep-apnoea-syndrome in France (Intranasal)
  • 11 Feb 2009 Phase-I clinical trials in Sleep apnoea syndrome in France (Intranasal)
  • 22 Apr 2008 Discontinued - Phase-II for Atrial fibrillation in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top